Drug Profile
FE 999310
Latest Information Update: 01 Apr 2021
Price :
$50
*
At a glance
- Originator Ferring Pharmaceuticals
- Class Infertility therapies
- Mechanism of Action Chorionic gonadotropin stimulants; Ovarian follicle stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Female infertility
- No development reported Infertility
Most Recent Events
- 18 Mar 2021 No development reported - Phase-II for Infertility (unspecified route)
- 18 Mar 2021 Phase-II clinical trials in Female infertility in Belgium, Czech Republic, Denmark, Spain, United Kingdom (SC) (NCT03564509)
- 08 Jan 2020 Ferring Pharmaceuticals completes a phase II trial in Female infertility in Belgium, Czech Republic, Denmark, Spain, United Kingdom (SC) (NCT03564509) (EudraCT2017-003810-13)